Elizabeth Lowe

10.9k total citations · 3 hit papers
51 papers, 3.6k citations indexed

About

Elizabeth Lowe is a scholar working on Oncology, Genetics and Reproductive Medicine. According to data from OpenAlex, Elizabeth Lowe has authored 51 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 27 papers in Genetics and 25 papers in Reproductive Medicine. Recurrent topics in Elizabeth Lowe's work include PARP inhibition in cancer therapy (31 papers), Ovarian cancer diagnosis and treatment (25 papers) and BRCA gene mutations in cancer (24 papers). Elizabeth Lowe is often cited by papers focused on PARP inhibition in cancer therapy (31 papers), Ovarian cancer diagnosis and treatment (25 papers) and BRCA gene mutations in cancer (24 papers). Elizabeth Lowe collaborates with scholars based in United States, United Kingdom and Italy. Elizabeth Lowe's co-authors include Claire Watkins, Michael Friedländer, Jean‐Yves Douillard, Mark A. Socinski, Vera Hirsh, Tony Mok, Yi‐Long Wu, Radj Gervais, Alison Armour and Frances A. Shepherd and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Elizabeth Lowe

49 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Edward S. Kim, Vera Hirsh et al. The Lancet profile →
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

2014 426 citations Amit M. Oza, David Cibula et al. The Lancet Oncology profile →
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth Lowe United States	19	2.8k	1.4k	1.1k	998	726	51	3.6k
Darren Hodgson United Kingdom	21	2.3k 0.8×	782 0.5×	1.4k 1.3×	925 0.9×	704 1.0×	73	3.1k
M. William Audeh United States	16	4.1k 1.5×	826 0.6×	2.7k 2.5×	998 1.0×	1.6k 2.1×	35	5.2k
Bethan Powell United States	6	1.6k 0.6×	339 0.2×	1.8k 1.7×	663 0.7×	708 1.0×	10	2.9k
Karin Bowen United States	15	1.3k 0.5×	942 0.7×	809 0.8×	334 0.3×	342 0.5×	30	2.8k
Sreenivasa Nattam United States	20	1.9k 0.7×	1.0k 0.7×	760 0.7×	418 0.4×	121 0.2×	42	2.6k
Sarah Runswick United Kingdom	9	2.3k 0.8×	932 0.6×	1.3k 1.2×	117 0.1×	820 1.1×	18	3.0k
Giorgio Valabrega Italy	28	1.8k 0.7×	490 0.3×	946 0.9×	394 0.4×	150 0.2×	115	2.8k
Jacqui Rowbottom United Kingdom	10	1.2k 0.4×	791 0.5×	567 0.5×	271 0.3×	215 0.3×	14	1.6k
J. Thaddeus Beck United States	29	2.6k 0.9×	1.3k 0.9×	1.3k 1.2×	288 0.3×	145 0.2×	113	3.7k
Yaroslav Shparyk United States	24	3.0k 1.1×	2.4k 1.6×	870 0.8×	131 0.1×	302 0.4×	70	3.9k

Countries citing papers authored by Elizabeth Lowe

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Lowe more than expected).

Fields of papers citing papers by Elizabeth Lowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Lowe. The network helps show where Elizabeth Lowe may publish in the future.

Co-authorship network of co-authors of Elizabeth Lowe

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Lowe. A scholar is included among the top collaborators of Elizabeth Lowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Lowe. Elizabeth Lowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scambia, Giovanni, Ricardo Villalobos-Valencia, Nicoletta Colombo, et al.. (2024). Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. Journal of Clinical Oncology. 43(12). 1408–1416. 1 indexed citations

Gebski, Val, Florence Joly, Jonathan A. Ledermann, et al.. (2024). Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer. Gynecologic Oncology. 192. 50–55.

Lee, Jung‐Min, Richard G. Moore, Sharad Ghamande, et al.. (2022). Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial. Clinical Cancer Research. 28(19). 4186–4193. 33 indexed citations

DiSilvestro, Paul, Susana Banerjee, N. Colombo, et al.. (2022). 517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial. Annals of Oncology. 33. S779–S779. 5 indexed citations

Banerjee, Susana, Kathleen N. Moore, Nicoletta Colombo, et al.. (2020). 811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology. 31. S613–S613. 47 indexed citations

Friedländer, Michael, Nicoletta Colombo, Giovanni Scambia, et al.. (2020). 234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology. 31. S1334–S1334. 1 indexed citations

Moore, Kathleen N., Nicoletta Colombo, Giovanni Scambia, et al.. (2018). Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. Annals of Oncology. 29. viii727–viii727. 7 indexed citations

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Oncology. 17(11). 1579–1589. 309 indexed citations breakdown →

Balmañà, Judith, Nadine Tung, Steven J. Isakoff, et al.. (2014). Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Annals of Oncology. 25(8). 1656–1663. 126 indexed citations

10.

Oza, Amit M., David Cibula, Christopher Poole, et al.. (2014). Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The Lancet Oncology. 16(1). 87–97. 426 indexed citations breakdown →

11.

Frank, Steven J., Ezra E.W. Cohen, Fred R. Hirsch, et al.. (2014). Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head & Neck. 38(3). 439–447. 16 indexed citations

12.

Kuter, Irene, Julia M.W. Gee, Roberto Hegg, et al.. (2012). Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Research and Treatment. 133(1). 237–246. 67 indexed citations

13.

Kaye, Stan B., Jan Lubiński, Ursula A. Matulonis, et al.. (2011). Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer. Journal of Clinical Oncology. 30(4). 372–379. 378 indexed citations

14.

Gross, Mitchell E., Lawrence Leichman, Elizabeth Lowe, Alan Swaisland, & David B. Agus. (2011). Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemotherapy and Pharmacology. 69(1). 273–280. 11 indexed citations

15.

Mazaheri, Parisa, et al.. (2010). Ghosal hematodiaphyseal dysplasia: A rare cause of a myelophthisic anemia. Pediatric Blood & Cancer. 55(6). 1187–1190. 13 indexed citations

16.

Kim, Edward S., Vera Hirsh, Tony Mok, et al.. (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet. 372(9652). 1809–1818. 1009 indexed citations breakdown →

17.

Douillard, Jean‐Yves, Vera Hirsh, Tony Mok, et al.. (2008). Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). Journal of Clinical Oncology. 26(15_suppl). 8001–8001. 27 indexed citations

18.

Lowe, Elizabeth, et al.. (2008). The Aromatase Inhibitor Anastrozole Is Ineffective in the Treatment of Precocious Puberty in Girls with McCune-Albright Syndrome. The Journal of Clinical Endocrinology & Metabolism. 93(7). 2751–2754. 35 indexed citations

19.

Douillard, Jean‐Yves, Edward Kim, Vera Hirsh, et al.. (2007). PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). Journal of Thoracic Oncology. 2(8). S305–S306. 71 indexed citations

20.

Kitchen, Brenda J., Asher Moser, Elizabeth Lowe, et al.. (1999). Thioguanine Administered as a Continuous Intravenous Infusion to Pediatric Patients Is Metabolized to the Novel Metabolite 8-Hydroxy-Thioguanine. Journal of Pharmacology and Experimental Therapeutics. 291(2). 870–874. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact